Advertisements


A blockbuster gene-editing tool has been linked to cancer — here"s how worried you should be

American Cancer Society/Getty Images Bold headlines linking blockbuster gene-editing tool CRISPR to cancer sent stocks in companies trying to bring the technology to medicine tumbling. But scientists who study the technique sa.....»»

Category: topSource: businessinsiderJun 13th, 2018

A blockbuster gene editing tool could cause more damage than experts thought

Bobby Yip/Reuters A new study has concluded that genetic editing tool, CRISPR-Cas9, can cause significantly greater havoc than exp.....»»

Category: topSource: businessinsiderJul 16th, 2018

Chinese Gene-Editing Trial Loses Track of Patients, Alarming Technology"s Inventors

A gene-editing trial in China lost touch with cancer patients whose DNA was altered, alarming some Western scientists who say subjects should be monitored for many years......»»

Category: asiaSource: wsjDec 29th, 2018

Scientists Just Found a Novel, Cheap Way to Use CRISPR Gene Editing to Fight Cancer

The CRISPR research was backed by Sean Parker's cancer immunotherap.....»»

Category: europeSource: fortuneJul 12th, 2018

CRISPR-related stocks sink after report that gene-editing technology might cause cancer

Shares of gene-therapy companies sank in active trade Monday, after a STAT report that editing a cell’s genome with CRISPR/Cas9 technology might cause cancer......»»

Category: topSource: marketwatchJun 11th, 2018

CRISPR Crashes After Study Highlights Potential Cancer Risk From Gene-Editing

Don't mess with mother nature.. or crowded longs! Crispr Therapeutics led gene-editing stocks lower after new studies published by Nature Medicine found that cells whose genomes are edited with the CRISPR-Cas9 technology have the po.....»»

Category: blogSource: zerohedgeJun 11th, 2018

Scientists can use CRISPR to edit genes. Should they?

Bill Whitaker reports on the gene-editing tool this week on 60 Minutes. The debate over how to use it is playing out in labs around the world.....»»

Category: topSource: moneycentralApr 30th, 2018

A Third Of The Great Barrier Reef Is Gone—Can Gene Editing Help Preserve The Rest?

By using a tool known as CRISPR-Cas9, scientists may be able to identify corals that are genetically predisposed to survive as the climate changes around them......»»

Category: topSource: newsweekApr 23rd, 2018

Why China Is the Brave New World of Editing Human DNA

The headline-making births last November of the world’s first gene-edited babies (twin girls) was unsurprising in one way: The scientist involved was from China. As part of its effort to dominate scientific spheres including biotechnology, Chin.....»»

Category: topSource: washpostJan 22nd, 2019

Editas CEO to step down amid management turnover at gene-editing firm

Katrine Bosley, the CEO of Cambridge gene editing company Editas Medicine Inc., announced she will be stepping down as of March, spurring a sell-off in the company's shares. The company says it has already started a search for a permanent replaceme.....»»

Category: topSource: bizjournalsJan 22nd, 2019

Britons Most at Risk in a Messy Split From EU Are Least Worried

Ahead of vital Brexit vote on Tuesday, many residents of U.K. manufacturing hubs closely linked to the bloc say they value their sovereignty above the economy......»»

Category: topSource: wsjJan 14th, 2019

Bill Gates warns that nobody is paying attention to gene editing, a new technology that could make inequality even worse

Jack Taylor/Getty Images) Bill Gates recently described a cutting-edge scie.....»»

Category: topSource: businessinsiderJan 12th, 2019

Crowded Cancer Space Triggers Big M&A Deals: More in Store?

Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in .....»»

Category: personnelSource: nytJan 8th, 2019

Homology Medicines advances first gene editing development candidate into study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 7th, 2019

Lilly to buy Loxo Oncology for about $8 billion in cancer bet

Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash, buying into a portfolio of targeted medicines to treat cancers caused by rare gene mutations......»»

Category: topSource: moneycentralJan 7th, 2019

Lilly to buy Loxo Oncology in $8 billion cancer push

Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash, buying into a portfolio of targeted medicines to treat cancers caused by rare gene mutations......»»

Category: topSource: reutersJan 7th, 2019

Bristol-Myers buys Celgene for $74 billion

Bristol-Myers Squibb is buying Celgene for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy sector heats up. Fred Katayama reports......»»

Category: videoSource: reutersJan 3rd, 2019

Bristol-Myers bulks up cancer portfolio with $74 billion Celgene deal

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy space heats up......»»

Category: topSource: reutersJan 3rd, 2019

Merck’s Blockbuster Cancer Drug Keytruda Wins Multiple Approvals in Japan

Merck shares were relatively unchanged early on Thursday after the firm announced that its blockbuster drug Keytruda reported a series of approvals in Japan......»»

Category: blogSource: 247wallstJan 3rd, 2019

Drugmaker Bristol-Myers to buy Celgene for $74 billion

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion in a cash-and-stock deal, creating a powerhouse that will have several blockbuster cancer drugs......»»

Category: topSource: reutersJan 3rd, 2019

CFO of gene editing biotech Editas leaving for Bain

Editas Medicine's chief financial officer is leaving the gene editing biotech in early 2019, returning to the investment industry with a position at Bain Capital. Editas (Nasdaq: EDIT) said Friday that Andrew Hack will leave on March 1 to take a po.....»»

Category: topSource: bizjournalsDec 21st, 2018